A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
Clinical trial NCT04209855 · COMPLETED
Trial details
- NCT number
- NCT04209855
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-31
- Primary completion
- 2023-03-06
- Enrollment
- 453
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.